

PRESS RELEASE

Settlement-delivery of the share capital increase by EOS imaging for an amount of €15M entirely subscribed by FOSUN PHARMACEUTICAL AG

Paris, December 11th, 2018, 6pm CET – EOS imaging (Euronext, FR0011191766 - EOSI - Eligible PEA - PME), the pioneer of 2D/3D imaging and data solutions for orthopedics, previously announced in a press release dated December 7th, 2018 the completion of a share capital increase (the "**Share Capital Increase**") for an amount of €15,061,856.13 through the issuance of 3,446,649 new shares at a subscription price of €4.37 per share entirely subscribed by Fosun Pharmaceutical AG, an indirect subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Fosun Pharma, stock code: 600196.SH, 02196.HK).

EOS imaging announces today the success of the settlement-delivery of the Share Capital Increase. The share capital of EOS imaging consequently amounts €261,304.07 divided into 26,130,407 shares. The new shares are assimilated to the existing shares of EOS imaging and are admitted today to trading on the regulated market of Euronext Paris under ISIN FR0011191766 – EOSI.

Further to the Share Capital Increase, Fosun Pharma, through Fosun Pharmaceutical AG, owns approximately 13.2% of the share capital and voting rights of EOS imaging (on a non diluted basis and taking into account the share capital and voting rights of the Company as of the date of this press release) and becomes the largest shareholder of EOS imaging.

For more information, please visit www.eos-imaging.com.

EOS imaging has been selected to integrate the EnterNext © PEA - PME 150 index, composed of 150 French, listed companies on Euronext and Alternext markets in Paris.

EOS imaging is listed on the Compartiment C of Euronext Paris
ISIN: FR0011191766 – Mnémo: EOSI



About EOS imaging

EOS imaging designs, develops and markets EOS®, a major innovative medical imaging solution dedicated to osteoarticular pathologies and orthopedics combining equipment and services and targeting a \$2B per year market opportunity. EOS imaging is currently present in 33 countries, including the United States(FDA), Japan, China and the European Union(CE), through the over 280 installed EOS® platforms representing more than one million patient exams every year. Revenues were €37.1M in 2017, e.g. a +32% CAGR over 2012-2017.

CONTACTS:

EOS imaging

Valérie Worrall

CFO

Ph: +33 (0) 1 55 25 60 60

investors@eos-imaging.com